Key result
In-hospital vericiguat initiation is linked to ~74% lower CV death or HF rehospitalization in HFrEF.
Why the study?
Hospitalization for the first episode of HFrEF is an important opportunity to initiate evidence-based therapies, but the role of vericiguat after first hospitalization is unclear.
Does vericiguat initiation reduce the composite of cardiovascular death or HF rehospitalization in adults at their first hospitalization for HFrEF?
Cohort (n=310)
Yes
Does vericiguat initiation reduce the composite of cardiovascular death or HF rehospitalization in adults at their first hospitalization for HFrEF?
Answers are grounded in this paper and cite their sources.
In a real-world Japanese cohort, early initiation of vericiguat during the first hospitalization for HFrEF was associated with a significantly lower risk of cardiovascular death or heart failure rehospitalization.
Background: Hospitalization for the first episode of heart failure with reduced ejection fraction (HFrEF) represents an important opportunity to initiate evidence-based therapies. In this study, we aimed to clarify the role of vericiguat after first hospitalization for HFrEF in routine clinical practice. Methods and Results: This multicenter retrospective cohort study included patients with HFrEF at their first hospitalization between June 2021 and September 2023 identified from the nationwide Verifying Characteristics and Outcomes in Heart Failure Patients Treated with Vericiguat registry (vericiguat group, n=104) and 2 institutional databases (control group, n=206) (mean age, 67 years; 71% male). The primary endpoint was a composite of cardiovascular death or HF rehospitalization within 1 year. In inverse probability of treatment weighting-adjusted Cox models, vericiguat use was associated with a lower risk of the primary endpoint, compared with controls (hazard ratio, 0.26; 95% confidence interval, 0.08–0.81). Sensitivity analysis using alternative weighting methods and a doubly robust model yielded consistent results. Conclusions: In this real-world Japanese cohort of patients at first hospitalization for HFrEF, vericiguat initiation during index hospitalization was associated with a lower risk of cardiovascular death or HF rehospitalization after discharge. The observed association was directionally consistent with previous trials and pooled analyses, suggesting a potential benefit for this intermediate real-world population.
No takes yet. Share an insight, caveat, or question.
松添弘樹 et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=310). Vericiguat vs. Standard heart failure therapy without vericiguat was evaluated on Composite of cardiovascular death or heart failure rehospitalization after discharge (HR 0.26, 95% CI 0.08-0.81, p=0.020). Vericiguat initiation during index hospitalization for a first episode of HFrEF was associated with a lower risk of cardiovascular death or heart failure rehospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: